Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eli M Roth

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Future Cardiology|January 21, 2016
Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indicationsEli M Roth
Expert Opinion on Drug Safety|October 10, 2017
A safety evaluation of evolocumabEli M Roth
Future Cardiology|December 1, 2018
Alirocumab for low-density lipoprotein cholesterol loweringEli M Roth
Expert Opinion on Pharmacotherapy|December 7, 2014
ω-3 carboxylic acids for hypertriglyceridemiaEli M Roth
Future Cardiology|April 26, 2014
Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibodyEli M Roth, Philip Diller
Current Atherosclerosis Reports|April 29, 2010
Fish oil for primary and secondary prevention of coronary heart diseaseEli M Roth, William S Harris
Future Cardiology|January 22, 2015
ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeksEli M Roth, James M McKenney
Reviews in Cardiovascular Medicine|September 13, 2018
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and SafetyEli M Roth, Michael H Davidson
Clinical Therapeutics|August 18, 2015
Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C LevelsEli M Roth, Maja Bujas-Bobanovic, Michael J Louie, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 30, 2013
Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysisEli M Roth, Suzanne Oparil, Michael Melino, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Future Cardiology|January 21, 2016
Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indicationsEli M Roth
Expert Opinion on Drug Safety|October 10, 2017
A safety evaluation of evolocumabEli M Roth
Future Cardiology|December 1, 2018
Alirocumab for low-density lipoprotein cholesterol loweringEli M Roth
Expert Opinion on Pharmacotherapy|December 7, 2014
ω-3 carboxylic acids for hypertriglyceridemiaEli M Roth
Future Cardiology|April 26, 2014
Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibodyEli M Roth, Philip Diller
Current Atherosclerosis Reports|April 29, 2010
Fish oil for primary and secondary prevention of coronary heart diseaseEli M Roth, William S Harris
Future Cardiology|January 22, 2015
ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeksEli M Roth, James M McKenney
Reviews in Cardiovascular Medicine|September 13, 2018
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and SafetyEli M Roth, Michael H Davidson
Clinical Therapeutics|August 18, 2015
Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C LevelsEli M Roth, Maja Bujas-Bobanovic, Michael J Louie, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 30, 2013
Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysisEli M Roth, Suzanne Oparil, Michael Melino, et al.
Pageof 4